NCT01089062View on ClinicalTrials.gov

Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

December 31, 2010

Conditions
Healthy
Interventions
DRUG

MAP0004

1.0 mg orally inhaled MAP0004 administered in Treatment B as per protocol

DRUG

IV Placebo (Saline)

IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol

DRUG

Placebo Inhaler

Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.

DRUG

IV Dihydroergotamine Mesylate (DHE)

IV DHE administered in Treatment A as per protocol

Trial Locations (1)

27710

Duke Clinical Research Unit, Durham

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
collaborator

MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

INDUSTRY

lead

Allergan

INDUSTRY

NCT01089062 - Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure | Biotech Hunter | Biotech Hunter